This is a $1,084,824.00 firm-fixed-price definitive contract awarded to Ampersand Biosciences LLC, a woman-owned small business, by the National Institute of Allergy and Infectious Diseases (NIAID) on September 30, 2024. The contract is for the further characterization and validation of monoclonal antibodies to study respiratory diseases. The work will be performed in Upper St Reg, NY 12945, USA and has an ultimate completion date of September 29, 2026. This contract does not have a set-aside designation.
Generated 1/4/25, 9:02 AM